FLT3 and acute myeloid leukemia: However, when used in combination with standard of care “7 + 3” chemotherapy, midostaurin significantly prolongs overall survival as demonstrated in a phase 3 clinical trial with 717 patients, where FLT3-positive AML patients survived 49 months longer based on median survival and had a 5.2 month-improvement in event-free survival.